Idera Pharmaceuticals Announces Presentations of Preclinical Data on New Potential Oncology Applications of its TLR9 Agonists at
18 Avril 2007 - 3:30PM
Business Wire
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced two
presentations of data for two new potential applications in
oncology of its novel agonists of Toll-like receptor 9 (TLR9) at
the Annual Meeting of the American Association for Cancer Research
(AACR) being held in Los Angeles, CA, April 14-18, 2007. The first
presentation covered a preclinical study in which Idera�s lead
oncology candidate, IMO-2055, in combination with the multikinase
inhibitor sorafenib, showed enhanced antitumor activity compared to
either agent alone in a mouse xenograft model. The second
presentation covered a preclinical study in which an analog of
IMO-2055 optimized for mice was administered by the intranasal
route and showed potent antitumor activity in mouse models of lung
metastases of colon carcinoma and melanoma. �The new data in a
mouse model show IMO-2055 has additive antitumor activity with
sorafenib, and adds to our previous data of additive antitumor
activity by IMO-2055 observed in combination with other targeted
agents such as VEGF and EGFR inhibitors,� said Robert W. Karr,
M.D., President of Idera. �Our new data on intranasal delivery show
promise for a potential new route of administration specifically to
treat lung tumors.� Abstract 4771 entitled, �The combination of
IMO-2055, a synthetic agonist of toll-like receptor-9 (TLR9), and
the multikinase inhibitor sorafenib tosylate (Nexavar�)
demonstrates enhanced antitumor activity in a human non-small cell
lung cancer xenograft model,� was presented by Bernardo Chavira of
TGen Drug Development Services in the session Cancer Therapeutics
2. The combination of IMO-2055 and sorafenib in the study lead to
increased antitumor effects and increased survival, with survival
means of 30.0 days in the IMO-2055 group, 27.8 days in the
sorafenib group and 41.3 days in the combination group (P
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Idera Pharmaceuticals (American Stock Exchange): 0 recent articles
Plus d'articles sur Idera Pharmaceuticals, Inc.